9 completed, 2 terminated. 11 Phase 3, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 11 | Completed 9, Terminated 2 |
| Phase 2 | 3 | Completed 3 |
Follow Inappropriate ADH Syndrome: new trials by email Literature Review of Inappropriate ADH Syndrome trials Research Report on Inappropriate ADH Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study Empagliflozin 25mg, Placebo - SIAD - Syndrome of Inappropriate Antidiuresis, Hyponatremia | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 17 | 2017-12-15 | 2021-12-13 |
| A Multicenter Trial to Investigate the Efficacy and Safety of Tolvaptan in Patients With Hyponatremia in SIADH Tolvaptan Oral Tablet - Syndrome of Inappropriate Antidiuretic Hormone Secretion | Phase 3 | Completed | Otsuka Pharmaceutical Co., Ltd. | 16 | 2017-03-02 | 2020-11-02 |
| Effects of the SGLT2-inhibitor Empagliflozin on Patients With SIADH - the SAND Study Empagliflozin, Placebo - SIADH | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 88 | 2016-09-05 | 2019-06-13 |
| Effects of Empagliflozin an SGLT2-Inhibitor on Healthy Volunteers With Induced Hypotonic Hyponatremia - the DIVE Study Induced hypotonic hyponatremia - SIAD model, Empagliflozin 25mg Tbl, Placebo P-Tablet - Inappropriate ADH Syndrome | Phase 2 / Phase 3 | Completed | University Hospital, Basel, Switzerland | 15 | 2016-03-01 | 2016-08-10 |
| Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia tolvaptan, Fluid Restriction - Hyponatremia, Dilutional Hyponatremia | Phase 3 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 124 | 2010-10-01 | 2014-10-30 |
| A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hyponatremia Lixivaptan, Placebo - Euvolemic Hyponatremia | Phase 3 | Completed | CardioKine Inc. | 206 | 2009-06-01 | 2011-06-28 |
| A Phase III Study Evaluating the Efficacy and Safety of Satavaptan Versus Placebo in Patients With Dilutional Hyponatremia Satavaptan, placebo - Hyponatremia, Inappropriate ADH Syndrome | Phase 3 | Terminated | Sanofi | 2 | 2008-07-01 | 2016-05-26 |
| Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion SR121463B - Inappropriate ADH Syndrome, Hyponatremia | Phase 3 | Completed | Sanofi | 57 | 2005-07-01 | 2009-01-21 |
| Efficacy and Safety of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion SR121463B - Inappropriate ADH Syndrome, Hyponatremia | Phase 3 | Completed | Sanofi | 77 | 2004-05-01 | 2008-12-10 |
| Study of Ascending Levels of Tolvaptan in Hyponatremia Tolvaptan, Placebo - Hyponatremia | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 243 | 2003-11-01 | 2026-07-13 |
| "SALT Trial" Study of Ascending Levels of Tolvaptan in Hyponatremia tolvaptan, placebo matching tolvaptan - Hyponatremias, Water Intoxication | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 205 | 2003-04-01 | 2026-07-13 |
Hyponatremia (9) · Diabetes Insipidus (2) · Fibrosis (2) · Heart Failure (1) · Water Intoxication (1) · Water-Electrolyte Imbalance (1)
Brain Diseases (11) · Central Nervous System Diseases (11) · Endocrine System Diseases (11) · Hypothalamic Diseases (11) · Metabolic Diseases (11) · Nervous System Diseases (11) · Nutritional and Metabolic Diseases (11) · Pituitary Diseases (11) · Water-Electrolyte Imbalance (10) · Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Kidney Diseases (2) · Male Urogenital Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Tolvaptan (4) · empagliflozin (3) · satavaptan (3) · Tablets (1) · lixivaptan (1)
Otsuka Pharmaceutical Development & Commercialization, Inc. (3) · Sanofi (3) · University Hospital, Basel, Switzerland (3) · CardioKine Inc. (1) · Otsuka Pharmaceutical Co., Ltd. (1)
United States (6) · Switzerland (4) · Belgium (3) · Germany (3) · Brazil (2) · Canada (2) · Hong Kong (2) · Hungary (2) · Australia (1) · Croatia (1) · Czechia (1) · France (1) · India (1) · Israel (1) · Italy (1)
Ann Dandurand, MD (1) · Frank Czerwiec, MD, PhD (1) · Mirjam Christ-Crain, Prof. (1) · Mirjam Christ-Crain, Prof. Dr. MD (1) · Mirjam Christ-Crain, Prof., MD (1) · Nestor Molfino, MD (1)
PMID 17105757, PMID 22027579, PMID 25151571, PMID 34412521, PMID 36396331, PMID 37098131, PMID 42522233
2015 (1), 2017 (1)